Denali Therapeutics Stock Analysis
| DNLI Stock | USD 24.69 0.47 1.94% |
Denali Therapeutics is undervalued with Real Value of 31.7 and Target Price of 55.6. The main objective of Denali Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Denali Therapeutics is worth, separate from its market price. There are two main types of Denali Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Denali Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Denali Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Denali |
Denali Stock Analysis Notes
About 91.0% of the company shares are held by institutions such as insurance companies. The book value of Denali Therapeutics was currently reported as 9.17. The company recorded a loss per share of 2.76. Denali Therapeutics had not issued any dividends in recent years. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Denali Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To learn more about Denali Therapeutics call Ryan Watts at 650 866 8548 or check out https://www.denalitherapeutics.com.Denali Therapeutics Investment Alerts
| Denali Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 330.53 M. Net Loss for the year was (145.22 M) with loss before overhead, payroll, taxes, and interest of (250.27 M). | |
| Denali Therapeutics currently holds about 1.07 B in cash with (357.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66. | |
| Denali Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Denali Therapeutics Inc. Receives 38.90 Consensus Target Price from Brokerages - MarketBeat |
Denali Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Denali Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Denali Largest EPS Surprises
Earnings surprises can significantly impact Denali Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-08 | 2022-06-30 | -0.55 | -0.48 | 0.07 | 12 | ||
2024-05-07 | 2024-03-31 | -0.7 | -0.78 | -0.08 | 11 | ||
2023-11-07 | 2023-09-30 | -0.8 | -0.72 | 0.08 | 10 |
Denali Therapeutics Environmental, Social, and Governance (ESG) Scores
Denali Therapeutics' ESG score is a quantitative measure that evaluates Denali Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Denali Therapeutics' operations that may have significant financial implications and affect Denali Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Denali Therapeutics Thematic Classifications
In addition to having Denali Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Pharmaceutical ProductsUSA Equities from Pharmaceutical Products industry as classified by Fama & French |
Denali Stock Institutional Investors
| Shares | Geode Capital Management, Llc | 2024-09-30 | 3 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.4 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 2.4 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 2.3 M | Alliancebernstein L.p. | 2024-06-30 | 2 M | Camber Capital Management Llc | 2024-09-30 | 2 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.6 M | Bank Of New York Mellon Corp | 2024-06-30 | 1.5 M | Principal Financial Group Inc | 2024-09-30 | 1.2 M | Baillie Gifford & Co Limited. | 2024-09-30 | 13.3 M | Blackrock Inc | 2024-06-30 | 13.2 M |
Denali Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.55 B.Denali Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.13) | (0.13) | |
| Return On Capital Employed | (0.18) | (0.19) | |
| Return On Assets | (0.13) | (0.13) | |
| Return On Equity | (0.14) | (0.15) |
Management Efficiency
Denali Therapeutics has return on total asset (ROA) of (0.2381) % which means that it has lost $0.2381 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3509) %, meaning that it created substantial loss on money invested by shareholders. Denali Therapeutics' management efficiency ratios could be used to measure how well Denali Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.13. The current Return On Capital Employed is estimated to decrease to -0.19. As of now, Denali Therapeutics' Non Current Assets Total are increasing as compared to previous years. The Denali Therapeutics' current Non Currrent Assets Other is estimated to increase to about 19.1 M, while Total Assets are projected to decrease to under 932.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.50 | 13.43 | |
| Tangible Book Value Per Share | 7.50 | 13.43 | |
| Enterprise Value Over EBITDA | (15.96) | (15.17) | |
| Price Book Value Ratio | 2.86 | 2.17 | |
| Enterprise Value Multiple | (15.96) | (15.17) | |
| Price Fair Value | 2.86 | 2.17 | |
| Enterprise Value | 2.9 B | 2.1 B |
The decision-making processes within Denali Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 1.394 | Return On Assets (0.24) | Return On Equity (0.35) |
Technical Drivers
As of the 25th of November, Denali Therapeutics shows the Coefficient Of Variation of 3174.18, mean deviation of 2.35, and Downside Deviation of 3.67. Denali Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Denali Therapeutics Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Denali Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Denali Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Denali Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Denali Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Denali Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Denali Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Denali Therapeutics Outstanding Bonds
Denali Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Denali Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Denali bonds can be classified according to their maturity, which is the date when Denali Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Denali Therapeutics Predictive Daily Indicators
Denali Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Denali Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Denali Therapeutics Corporate Filings
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 7th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 22nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Denali Therapeutics Forecast Models
Denali Therapeutics' time-series forecasting models are one of many Denali Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Denali Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Denali Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Denali Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Denali shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Denali Therapeutics. By using and applying Denali Stock analysis, traders can create a robust methodology for identifying Denali entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.44) | (0.46) | |
| Operating Profit Margin | (0.60) | (0.62) | |
| Net Loss | (0.44) | (0.46) | |
| Gross Profit Margin | (0.28) | (0.30) |
Current Denali Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Denali analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Denali analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 55.6 | Strong Buy | 17 | Odds |
Most Denali analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Denali stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Denali Therapeutics, talking to its executives and customers, or listening to Denali conference calls.
Denali Stock Analysis Indicators
Denali Therapeutics stock analysis indicators help investors evaluate how Denali Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Denali Therapeutics shares will generate the highest return on investment. By understating and applying Denali Therapeutics stock analysis, traders can identify Denali Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 219.5 M | |
| Common Stock Shares Outstanding | 137.4 M | |
| Total Stockholder Equity | 1 B | |
| Tax Provision | -6000.00 | |
| Property Plant And Equipment Net | 71.6 M | |
| Cash And Short Term Investments | 1 B | |
| Cash | 127.1 M | |
| Accounts Payable | 9.5 M | |
| Net Debt | -74.9 M | |
| 50 Day M A | 27.8774 | |
| Total Current Liabilities | 78 M | |
| Other Operating Expenses | 527.2 M | |
| Non Current Assets Total | 89.8 M | |
| Non Currrent Assets Other | 18.1 M | |
| Stock Based Compensation | 108.1 M |
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |